Related to Stanford v. Roche Could Place Tech Transfer on Shaky Ground

• Patent Reform Battle Pits Biotech against High-Tech
  The former fears increased infringement due to lower damages under the Patent Reform Act of 2009 making its way through Congress.
  
• Intellectual Property at Crossroads
  The convergence of the patent system with the regulatory system presents complicated issues.
  
• Potential Effects of Pending Biologics Legislation on the Patent Application Process
  While patent reform may get bumped to a later Congress, a resolution to biosimilars law may get passed as part of a healthcare reform bill.
  
• Market Exclusivity—Paramount in Evaluating Target Companies
  The main related factors are relevant facts, freedom to operate, IP, third-party agreements, and regulatory exclusivity.
  
• Tips for Managing Bribery and Corruption Risks
  Operations in emerging markets are particularly liable.
  
• New Uncertainty Regarding Disclosure of Adverse Effects
  Recent Matrixx Initiatives decision muddies requirements set forth in Carter-Wallace over a decade ago.
  
• 2009 in Review: Headline-Making Stories in the Biotech Industry
  Even though last year was marred by the economic crash, the life science sector showed significant progress.
  
• Roche Takes a Stab at Getting mAbs Under the Skin
  Firm is testing Herceptin SC in Phase III and expects to couple it with a user-friendly delivery device.
  
• Ocrelizumab: One Size Does Not Fit All
  Risk of serious infections has hampered mAb’s development in RA and LE, but drug is still being tested in MS.
  
• Lupus Drug Development Remains Risky Business
  Research to understand underlying causes is, nonetheless, prompting some interest.
  
• Avastin: Time for a Predictive Test
  Roche’s strategy to expand the use of Avastin into the first-line and adjuvant settings is particularly dependent on identifying those most likely to see a benefit.
  
• Court’s Halt of Federally Backed ESC Research May Impact Economic Growth
  If the injunction sticks, U.S. firms will likely send ESC research jobs abroad.
  
• Is Avastin Roche’s Achilles Heel?
  Label-expansion efforts have failed, and mAb stands to lose provisional approval in breast cancer.
  
• Weighing the Benefits of Rituximab Maintenance Therapy for FL
  Drug may be more cost-effective and improve PFS, but questions about overall survival remain.